Abstract 340: Predictive value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with chemotherapy (CT)

Abstract

Abstract Introduction: KRAS mutation is thought to be related with poor outcome of NSCLC pts. The predictive value of KRAS mutation for response to chemotherapy (CT) has not been established Patients and methods: From a retrospective database from 2 university hospitals all pts with advanced NSCLC treated with palliative platinum containing chemotherapy were selected. Pts were included when archive tumor tissue was available for DNA extraction. High resolution melting followed by PCR sequencing was performed for KRAS exon1 and 2. Results: KRAS mutation analysis was evaluable for 122 pts. All pts had advanced NSCLC and were no candidate for treatment with curative intent. Mean age 61 years (range 24-80 years), 81 males and 41 females. All pts received platinum-containing CT. Response was evaluable for 110 pts: 1 complete response, 21 partial response, 54 stable disease and 54 progressive disease. Median progression free survival (PFS) was 5.7 months (m) (95% CI 4.2-7.2 m), median overall survival (OS) was 7.5 m (94% CI 5.2-9.9 m). 44 pts (36%) had a KRAS mutation. 38% of pts with a KRAS mutation had as best response PD on CT, and 27% of pts without a KRAS mutation had PD, this difference was not significant. No difference in PFS and OS was observed for pts with a KRAS mutation (median PFS 5.3 m, 95% CI 3.2-7.3 m and median OS 6.2 m, 95% CI 4.8-7.3 m) and without a KRAS mutation (median PFS 6.1, 95% CI 5.0-7.2m and median OS 8.9 m, 95% CI 6.4-11.4). Conclusion: In our series KRAS mutation was not predictive for response to platinum containing CT in pts with advanced NSCLC. Furthermore, KRAS mutation was not prognostic. Additional data on specific KRAS mutations will be presented. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 340. doi:10.1158/1538-7445.AM2011-340